Xbrane Nears FDA Decision for Lucamzi Biosimilar
STOCKHOLM, Sweden, June 3, 2026 Xbrane Biopharma AB has reached a significant regulatory milestone after the U.S. Food and...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
STOCKHOLM, Sweden, June 3, 2026 Xbrane Biopharma AB has reached a significant regulatory milestone after the U.S. Food and...
WARSAW, Poland and BUENOS AIRES, Argentina, 22 May 2026 Polpharma Biologics has entered a major licensing agreement with Tuteur...
TORONTO, Ontario, Canada, April 7, 2026 Apotex Inc., a leading global pharmaceutical company, announced that Health Canada has approved...
SHANGHAI, China, April 1, 2026 Shanghai Henlius Biotech, Inc. announced that the China National Medical Products Administration (NMPA) has...
TEL AVIV, Israel & PARSIPPANY, N.J., USA, March 30, 2026 Teva Pharmaceutical Industries has received U.S. FDA approval for...
Budapest / London, September 29, 2025 Gedeon Richter and Hikma announced that the U.S. Food and Drug Administration (FDA)...
